The PETRARCA trial assessed the efficacy of adding trastuzumab and pertuzumab to perioperative FLOT chemotherapy in patients with HER2-positive GC and was prematurely closed after the same antibody combination did not meet its primary endpoint in a trial with metastatic GC.88 However, the pathological complete response rate was also significantly improved with this combination therapy. The gene discussed is ERBB2; the disease is gastric cancer.